GLP-1 News & Analysis
22 articles
Market Mood

Zepbound Users Gain Strength Despite Some Muscle Loss in Study
A new study finds that people taking Zepbound, a GLP-1 drug, who engage in consistent resistance training can still increase their strength even if they lose some muscle. This suggests that muscle loss does not necessarily impede strength gains for Zepbound users following resistance exercise routines. The study's findings provide important information for users of GLP-1 drugs concerned about muscle loss during treatment. These results may help inform exercise recommendations for patients on Zepbound and similar drugs. It highlights the potential for resistance training to maintain or improve functional strength despite muscle mass changes. Clinicians and patients may consider integrating resistance training to optimize health outcomes while on GLP-1 medication. For investors and users of GLP-1 drugs, this study matters because it addresses a key concern about muscle loss, a known side effect that could affect treatment adherence and perception. The ability to still gain strength implies resistance training could mitigate this side effect, potentially supporting wider acceptance of drugs like Zepbound.
Read More: Zepbound Users Gain Strength Despite Some Muscle Loss in Study
FDA Issues New Safety Warning on GLP-1 Drugs Like Ozempic and Wegovy
The U.S. Food and Drug Administration (FDA) has issued a new safety warning for GLP-1 drugs, which include popular medications such as Ozempic and Wegovy. These drugs, used primarily for diabetes and weight management, have been linked to serious complications including eye-related issues and stroke. The warning highlights potential risks that patients and healthcare providers should be aware of. Multiple outlets, including The Washington Post, Fast Company, and MedPage Today, have reported on the FDA's advisory. Ophthalmologists and experts from Johns Hopkins have also provided guidance on the risks associated with these drugs, emphasizing caution given new findings related to eye stroke and blindness. The warning reflects increased scrutiny of GLP-1 drugs amid growing usage. For investors and markets, the FDA’s safety warning may affect companies involved in manufacturing and selling GLP-1 drugs. Increased regulatory attention could impact sales or prescribing patterns of these treatments. Investors should monitor how these developments influence future drug approvals, sales, and potential liability costs for companies marketing GLP-1 medications.
Read More: FDA Issues New Safety Warning on GLP-1 Drugs Like Ozempic and Wegovy
CVS States GLP-1 Drugs Save Money Below $350 Monthly Price
CVS Health said glucagon-like peptide-1 (GLP-1) medications can save money if priced below $350 per month. The company highlighted the potential cost savings linked to GLP-1 drugs in managing chronic conditions. No further specific financial details or price comparisons were provided. This pricing benchmark reflects CVS's view on when GLP-1 medications become cost-effective for patients and payers. GLP-1 drugs are a class of medications often used to treat diabetes and obesity. CVS's statement indicates they see economic benefits if prices stay within this range, which may impact insurance coverage and patient access. No other companies or market impacts are detailed in the article. For investors, this suggests CVS is monitoring drug pricing closely and expects drug costs below $350 per month to be a key factor in realizing savings. The statement may influence payer negotiations and affect drug pricing strategies in the pharmaceutical sector.
Read More: CVS States GLP-1 Drugs Save Money Below $350 Monthly Price
FDA Requires Vision Loss Warnings on GLP-1 Drugs After Study
The U.S. Food and Drug Administration (FDA) is mandating new safety warnings on all GLP-1 drugs due to a potential increased risk of a rare eye condition, nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden vision loss. The FDA emphasized that NAION is rare and a direct causal link to these drugs has not been confirmed. The FDA's decision followed a review that included 126 clinical trials with over 134,000 patients. This review found 6.4 cases of NAION per 100,000 patient-years in users of GLP-1 drugs, compared with 3.8 cases per 100,000 patient-years among those receiving other treatments or placebos. The agency also considered real-world data and published studies that showed an increased risk of NAION with GLP-1 medications, including products from Novo Nordisk and Eli Lilly. This warning is significant as GLP-1 drugs like Wegovy, Ozempic, Mounjaro, Zepbound, and Foundayo are widely used for conditions like diabetes and weight management. The requirement for new warnings could affect prescribing practices and patient monitoring. Investors in companies producing GLP-1 drugs may see this as a regulatory development prompting closer attention to drug safety profiles and potential impacts on sales or litigation risks.
Read More: FDA Requires Vision Loss Warnings on GLP-1 Drugs After Study
FDA Requires Vision Loss Warnings for GLP-1 Weight Loss Drugs
The US Food and Drug Administration (FDA) has mandated that makers of GLP-1 weight loss drugs include new warnings about potential vision loss. This includes popular medications such as Ozempic and Zepbound, which must now carry alerts about a rare risk of blindness. Several news outlets, including The Washington Post, CNN, News4JAX, The Independent, and the Financial Times, reported on the FDA's decision. The move comes as the agency seeks to inform users of these drugs about serious eye-related side effects, although the exact likelihood and details of the risk were not specified in the reports. This development matters because GLP-1 drugs are widely prescribed for obesity and weight management, and new safety warnings could affect patient decisions and regulatory scrutiny. For investors and markets, these warnings could impact the sales and reputations of companies producing these drugs, potentially influencing future revenue streams and stock valuations. Overall, the FDA’s warning requirement highlights increasing regulatory attention to the safety profile of GLP-1 medications. Ordinary investors should note that these warnings could translate into changes in demand and risk perceptions for the affected drug makers, possibly influencing their financial results.
Read More: FDA Requires Vision Loss Warnings for GLP-1 Weight Loss Drugs
Novo Nordisk (NVO) Raises Annual Outlook on $11.9B Q3 Sales Beat
Novo Nordisk (NVO) reported third-quarter sales of 79.2 billion Danish kroner ($11.9 billion), surpassing FactSet estimates of 73.6 billion kroner. Sales grew 4% year-on-year at constant exchange rates. Adjusted operating profit came in at 31.7 billion kroner, ahead of the expected 28.6 billion kroner. The company upgraded its full-year outlook, now expecting adjusted revenue and operating profit growth between negative 2% and 2% on a constant currency basis. This is more optimistic than its earlier range of negative 6% to flat, which it revised upward in August. Strong sales of its Wegovy weight-loss pill at 5.4 billion kroner exceeded analyst expectations of about 4.5 billion kroner. Additional sales from injectable Wegovy and diabetes drug Ozempic also beat estimates, at 20.4 billion kroner and 29.7 billion kroner respectively. Novo is competing closely with Eli Lilly in the GLP-1 weight-loss drug market, where investor focus remains on next-generation treatments addressing obesity-linked diseases. The company also announced planned CFO Karsten Munk Knudsen’s departure at the end of 2026, with Luigi La Corte from Galderma named as his successor. Investors will watch how the improved sales momentum and outlook revisions might affect annual revenue and profit growth forecasts.
Read More: Novo Nordisk (NVO) Raises Annual Outlook on $11.9B Q3 Sales Beat
Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Eli Lilly CEO Dave Ricks reported that since the launch of Medicare coverage for obesity drugs in July, 700,000 new seniors have begun GLP-1 treatments, with 70% opting for Lilly medications. The coverage allows eligible seniors to access weight loss drugs for a $50 monthly co-pay. Lilly's Zepbound and Foundayo are noted as leading choices among patients, with one-third of new oral GLP-1 patients using Foundayo. The increase in patients shows significant market expansion for obesity treatments, which potentially benefits Eli Lilly (LLY) significantly.
Read More: Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
G20 Meeting: U.S. Tariffs and Debt Discussions Impacting Growth
During the G20 summit, U.S. Treasury Secretary Scott Bessent emphasized the need for the U.S. to grow its way out of a record national debt, which is in the tens of trillions of dollars. Despite the Supreme Court striking down various tariffs earlier this year, the U.S. has imposed a 50% import tax on many Canadian goods. Eli Lilly CEO Dave Ricks discussed that GLP-1 medications may not have fully penetrated the economy yet, with only 25 to 30 million users out of a potential billion globally. These developments suggest potential shifts in market dynamics affecting both tariffs and healthcare spending.
Read More: G20 Meeting: U.S. Tariffs and Debt Discussions Impacting Growth
Hims & Hers (HIMS) Reports 3% Stock Decline After Q2 Loss
Hims & Hers Health (HIMS) stock declined 3% before trimming losses on August 11, 2026. The company reported a loss of $0.37 per share in Q2, down from a profit of $0.17 per share in the same period last year, with gross margins decreasing to 64% from 76%. This performance was affected by a one-time cost of $81 million, associated with the acquisition of Eucalyptus and restructuring due to changes in their weight-loss strategy. These financial results highlight the ongoing regulatory challenges and shifts in strategy, which are significant for investors tracking the company's performance.
Read More: Hims & Hers (HIMS) Reports 3% Stock Decline After Q2 Loss
CVS Health (CVS) Earnings Report Upcoming Analysts Focus on GLP-1
CVS Health (CVS) is scheduled to report earnings soon, with analysts paying close attention to GLP-1 drug momentum. This class of medications has been gaining traction as a weight-loss treatment, potentially impacting CVS's performance. Investors are keen to see how this will influence the company's overall outlook and revenue streams. Monitoring the earnings report may help provide insights into market trends in the healthcare sector.
Read More: CVS Health (CVS) Earnings Report Upcoming Analysts Focus on GLP-1
Pague Menos Q2 2026 Reports Record Margins Amid GLP-1 Slowdown
In Q2 2026, Pague Menos reported record margins despite a slowdown in GLP-1 sales. The company achieved a profit margin of 15%, an increase from the previous quarter. This performance reflects the company's ability to adapt to market changes while managing costs effectively. The growth in margins can influence investor sentiment positively as it showcases operational efficiency. This is significant for investors as it indicates potential resilience in the company's financial health.
Read More: Pague Menos Q2 2026 Reports Record Margins Amid GLP-1 Slowdown
GLP-1 Users Return to In-Store Clothes Shopping Trips
The article discusses a trend among GLP-1 medication users returning to in-store shopping for clothes after weight loss associated with the drugs. There are observations of increased clothing purchases and trips to physical stores. This shift highlights changing consumer behavior linked to health improvements from GLP-1s. As more consumers spend money on fashion, this could positively impact companies in retail and related sectors.
Read More: GLP-1 Users Return to In-Store Clothes Shopping Trips
Galderma Reports Nearly 25% Growth Amid Botox Demand Increase
CEO Flemming Ørnskov announced that Galderma has seen nearly 25% sales growth year-on-year at constant currencies, attributed to the rising use of GLP-1 weight-loss drugs like Ozempic. Approximately one in 10 U.S. adults are now using these medications, creating strong demand for Galderma’s aesthetic products to combat facial volume loss associated with significant weight loss, informally known as 'Ozempic face.' Growth in the U.S. market was particularly notable at 32%, compared to 19% worldwide. This trend in increasing demand for cosmetic injectables may impact Galderma's market presence positively moving forward.
Read More: Galderma Reports Nearly 25% Growth Amid Botox Demand Increase
Medicare Access to GLP-1s for Weight Loss Starting July 1
Starting July 1, Medicare beneficiaries who qualify will have access to GLP-1 weight-loss drugs for a cost of $50 per month. This initiative marks a significant change in the coverage of weight management treatments for older Americans. The availability of these drugs could potentially influence the healthcare market by increasing demand for GLP-1 medications. It is important for beneficiaries to be aware of possible side effects associated with these treatments.
Read More: Medicare Access to GLP-1s for Weight Loss Starting July 1
Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
Goldman Sachs has maintained its Neutral rating and $47 price target on Novo Nordisk (NVO) after meeting with the management at the 47th Annual Global Healthcare Conference on June 9. This target represents a 7% upside from the closing price of 287.25 Danish kroner on June 12, which was up 1.66% for the day. Earlier this year, Novo shares dropped to a 52-week low near $37 following disappointing trial results for its drug CagriSema. Additionally, it held a 39% market share in the U.S. obesity and diabetes GLP-1 market, compared to Eli Lilly’s 60%.
Read More: Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
High-Protein Whey Shortage Drives Prices Up Amid GLP-1 Demand
The demand for high-protein whey has surged due to increased interest in wellness products and the GLP-1 medication boom. This spike has created a substantial shortage in supply, affecting nutrition companies across the market. As a result, prices are reportedly rising significantly, impacting profit margins for companies that produce whey-based products. The ongoing trend towards health and wellness further emphasizes the importance of monitoring the whey market for potential investments.
Read More: High-Protein Whey Shortage Drives Prices Up Amid GLP-1 Demand
Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Wegovy continues to lead the GLP-1 market among weight-loss medications, despite competition from Eli Lilly's Foundayo. Specific market share percentages or sales figures were not provided. This dominance highlights Wegovy's strong brand recognition and patient preference in a growing sector. The competitive landscape for GLP-1 medications may impact market valuations for companies involved in this space, including Eli Lilly (LLY).
Read More: Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More: Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
Over 600,000 prescriptions for Novo Nordisk's Wegovy (NVO) were written by February 2023, indicating increased demand for weight loss drugs. Currently, nearly 13% of U.S. adults are on a GLP-1 medication, with adoption rates increasing from 11% in November 2024 to 16% in November 2025. Retailers are reporting a rise in customers seeking new clothing due to weight loss, with specific interest noted by services like Stitch Fix. Analysts predict that as accessibility improves, consumer spending on apparel is expected to grow significantly, particularly for smaller sizes.
Read More: GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
GoodRx (GDRX) has announced that it will offer the Foundayo GLP-1 medication starting at a price of $149 per month. This move provides a lower-cost option for patients seeking weight management treatments. The availability of this medication may impact the market for weight-loss pharmaceuticals by introducing competition. As healthcare costs continue to be a focus for consumers and providers, this pricing could influence purchasing decisions in the sector.
Read More: GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More: Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions